Core Viewpoint - Southbound funds have significantly increased their holdings in MicroPort Medical (00853.HK), indicating strong investor interest and confidence in the company's future prospects [1] Group 1: Southbound Fund Activity - On January 23, southbound funds increased their holdings by 1.6216 million shares of MicroPort Medical [1] - Over the past five trading days, there have been four days of net increases, totaling 7.5492 million shares [1] - In the last 20 trading days, there were 16 days of net increases, amounting to 33.0996 million shares [1] - Currently, southbound funds hold 913 million shares of MicroPort Medical, representing a significant portion of the company's issued ordinary shares [1] Group 2: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.5917 million shares on January 22, 2026, marking a positive trend in investment interest [1] - Over the past five trading days, southbound funds have increased their holdings on four occasions, with a total net increase of 10.374 million shares [1] - In the last twenty trading days, there have been fifteen days of net increases in holdings, totaling 31.3323 million shares [1] Group 2 - As of January 22, 2026, southbound funds hold a total of 911 million shares of MicroPort Medical, which represents a significant portion of the company's issued ordinary shares [1] - The daily changes in shareholding for the last five trading days show fluctuations, with the largest increase being 4.4877 million shares on January 19, 2026, and a decrease of 2.0648 million shares on January 20, 2026 [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight business segments including cardiovascular intervention, orthopedic medical devices, and surgical robotics [2]

Core Viewpoint - Southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.4078 million shares on January 8, 2026, indicating a positive trend in investor sentiment towards the company [1]. Group 1: Shareholding Changes - Over the past five trading days, Southbound funds have increased their holdings for five days, with a total net increase of 20.3882 million shares [1]. - In the last twenty trading days, there were seven days of net reduction in holdings, totaling 442,100 shares [1]. - As of now, Southbound funds hold 904 million shares of MicroPort Medical, accounting for 47.24% of the company's total issued ordinary shares [1]. Group 2: Shareholding Data - On January 8, 2026, the total number of shares held was 904 million, with a change of 3.4078 million shares, reflecting a 0.38% increase [2]. - On January 7, 2026, the total number of shares held was 901 million, with a change of 2.0976 million shares, reflecting a 0.23% increase [2]. - On January 5, 2026, the total number of shares held was 898 million, with a change of 3.3146 million shares, reflecting a 0.37% increase [2]. - On January 2, 2026, the total number of shares held was 2,556.8 million, with a change of 9.0958 million shares, reflecting a 1.03% increase [2]. - On December 30, 2025, the total number of shares held was 886 million, with a change of 2.4725 million shares, reflecting a 0.28% increase [2]. Group 3: Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight divisions [2]. - The cardiovascular intervention division includes products such as implantable devices and access devices [2]. - The orthopedic medical device division includes instruments for joint reconstruction and spinal applications [2]. - The cardiac rhythm management (CRM) division includes devices such as pacemakers and defibrillators [2]. - The aortic and peripheral vascular intervention division includes products like the "L-REBOA" aortic occlusion balloon [2]. - The neuro-intervention division includes products for treating cerebral artery atherosclerosis and coils [2]. - The structural heart disease division includes products for transcatheter aortic valve implantation [2]. - The surgical robotics division is involved in the manufacturing and R&D of surgical robotic instruments [2]. - The surgical medical device division focuses on the manufacturing and R&D of surgical medical devices [2].

Group 1 - The core point of the article is that southbound funds have increased their holdings in MicroPort Medical (00853.HK) by 3.31 million shares on January 5, 2026, with a total net increase of 16.43 million shares over the past five trading days [1] - Over the last 20 trading days, there were 7 days of net reductions in holdings, totaling 1.05 million shares [1] - As of now, southbound funds hold 899 million shares of MicroPort Medical, accounting for 46.96% of the company's total issued ordinary shares [1] Group 2 - The total number of shares held by southbound funds on January 5, 2026, was 899 million, reflecting a change of 3.31 million shares, which is a 0.37% increase [2] - The previous trading days showed significant changes, with an increase of 9.10 million shares (1.03%) on January 2, 2026, and smaller increases on December 30, 2025 (0.28%), December 29, 2025 (0.16%), and December 23, 2025 (0.02%) [2] - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices, operating through eight divisions including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, and surgical robotics [2]

Group 1 - Southbound funds reduced their holdings in MicroPort Scientific Corporation (00853.HK) by 4.6228 million shares on December 17 [1] - Over the past 5 trading days, there have been 5 days of net reductions by southbound funds, totaling 26.6461 million shares [1] - In the last 20 trading days, there were 8 days of net reductions, amounting to 16.1669 million shares [1] Group 2 - As of now, southbound funds hold 880 million shares of MicroPort Scientific Corporation, representing 45.98% of the company's issued ordinary shares [1] - MicroPort Scientific Corporation is primarily engaged in the sales, production, research, and development of medical devices [1] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [1]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 310,000 shares on December 9, with a total net increase of 5.3182 million shares over the last five trading days [1] - Over the past 20 trading days, there were 15 days of net increases, totaling 14.1728 million shares [1] - As of now, southbound funds hold 907 million shares of MicroPort Medical, accounting for 47.42% of the company's total issued ordinary shares [1] Company Overview - MicroPort Medical Science Co., Ltd. is primarily engaged in the sales, production, research, and development (R&D) of medical devices [1] - The company operates through eight divisions, including: - Cardiovascular Interventional Business: Products include implantable devices and access devices [1] - Orthopedic Medical Devices: Focuses on joint reconstruction and spinal instruments [1] - Cardiac Rhythm Management (CRM): Involves pacemakers and defibrillators [1] - Aortic and Peripheral Vascular Interventional Business: Includes products like the "L-REBOA" aortic occlusion balloon [1] - Neurointerventional Business: Products for treating cerebral artery atherosclerosis and coils [1] - Structural Heart Disease Business: Involves transcatheter aortic valve implantation [1] - Surgical Robotics Business: Engaged in the manufacturing and R&D of surgical robotic devices [1] - Surgical Medical Devices: Focuses on the manufacturing and R&D of surgical medical instruments [1]

Core Insights - Southbound funds increased their holdings in MicroPort Medical (00853.HK) by 2.36 million shares on December 3, 2025, marking a total net increase of 10.81 million shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have increased their holdings on 12 occasions, resulting in a cumulative net increase of 8.71 million shares [1] - As of now, southbound funds hold 904 million shares of MicroPort Medical, accounting for 47.27% of the company's total issued ordinary shares [1] Summary by Category Shareholding Changes - On December 3, 2025, total shares held reached 904 million, with a change of 2.36 million shares, representing a 0.26% increase [2] - On December 2, 2025, total shares held were 902 million, with a change of 2.54 million shares, representing a 0.28% increase [2] - On December 1, 2025, total shares held were 276.68 million, with a change of 361,100 shares, representing a 0.04% increase [2] - On November 28, 2025, total shares held were 266.8 million, with a change of 1.55 million shares, representing a 0.17% increase [2] - On November 27, 2025, total shares held were 898 million, with a change of 4 million shares, representing a 0.45% increase [2] Company Overview - MicroPort Medical is primarily engaged in the sales, production, research, and development of medical devices [2] - The company operates through eight divisions, including cardiovascular intervention, orthopedic medical devices, cardiac rhythm management, large artery and peripheral vascular intervention, neurointervention, structural heart disease, surgical robotics, and surgical medical devices [2]

Core Viewpoint - The company has successfully transitioned to a profitable phase in 2024, showcasing strong commercialization capabilities and resilience in profitability through differentiated product layout, efficient cost control, and a global strategic vision [1][2]. Financial Performance - In the first half of the year, the company achieved revenue of 186 million RMB, a year-on-year increase of 44.4%, driven by the collaborative performance of three major business lines [3]. - The net profit reached 50.94 million RMB, reversing the loss from the same period last year, with operating cash flow rising to 53.6 million RMB, indicating a sustainable self-sustaining development phase [4]. - The gross margin improved by 4 percentage points to 68.2%, reflecting enhanced production process maturity and cost optimization from scale effects [4]. - The sales and management expense ratio decreased from 44.8% to 37%, marking a transition from high investment in market expansion to a new phase of efficiency improvement [4]. Research and Development - The company focused R&D resources on core pipelines, resulting in a 35.1% decrease in R&D expenses to 20.62 million RMB, while accelerating the approval and market entry of key products [5][10]. - The complete commercialization of core product matrices, including devices for hemorrhagic stroke treatment, has established a competitive barrier against imported brands [11]. Global Expansion - The company has accelerated its internationalization process, obtaining CE or FDA certifications for several products and registering approximately 100 products in 21 countries [16]. - The global strategy aligns with the industry's growth window, as the demand for medical infrastructure in emerging markets and the cost-performance advantage of Chinese devices create a favorable environment for expansion [18]. Market Dynamics - The continuous improvement in the company's fundamentals resonates with positive signals from the capital market, reflecting a reconstruction opportunity in the innovative medical device industry [20]. - The recent recovery in the Hong Kong pharmaceutical sector, with the Hang Seng Healthcare Index rising over 100% this year, indicates a consensus on the industry's turning point [20][23]. - The combination of accelerated approvals and optimized payment policies is expected to benefit companies like the company that possess both innovative strength and profitability resilience [23]. Valuation Potential - Despite a stock price increase of over 300% in the past year, the company's valuation remains at historical low levels, suggesting that its growth potential is not fully reflected in the current stock price [24]. - The company is entering a critical phase of value reassessment, supported by comprehensive financial improvements, a dense pipeline of innovations, and steady progress in global expansion [24].